Q&A with Rao Tatapudy, Catalent - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Rao Tatapudy, Catalent
A Q&A with Rao Tatapudy, vice-president of scientific affairs at Catalent, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 10, pp. 140

PharmTech:



What is the biggest industry challenge you're now facing?

Tatapudy:

The productivity and efficiency of internal drug development have become big challenges in the industry. These challenges arise from the large size of a few Big Pharma companies (which results from consolidation), the emergence of several large generic-drug players, long approval times for both branded and generic products, and a short patent life for new drugs. This situation is an opportunity for global drug-development and delivery companies that support the pharmaceutical industry. By offering support for a product's entire life cycle, including preformulation, product development, clinical supplies, commercialization, analytical services, packaging services, and regulatory support, these companies can position themselves to succeed in the current environment.

PharmTech:

Do you see a new industry trend emerging?

Tatapudy:

Yes. Big Pharma is struggling with extensive talent on hand and limited product-development budgets, partly because of mergers and acquisitions, and partly because fewer and fewer new drug applications are being filed each year. On the other hand, global drug-development and delivery companies are extremely enthusiastic about the prospects for growth and innovation and have expanded their horizons to serve the entire industry across most dosage forms. In particular, because a large majority of new molecules in development are BCS class II and IV compounds with significant bioavailability challenges, highly specialized expertise in drug development, delivery, and manufacturing will be needed, and this situation will require drug innovators to work closely with specialty drug delivery companies such as Catalent.

PharmTech:

What is the most common demand your clients are currently making of you?

Tatapudy:

Our customers approach us for more products, better treatments, reliably supplied. Many customers come to Catalent for help in solving their bioavailability, solubility, and permeability challenges.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here